Onureg

Bristol Myers Squibb (BMS) is a premier global biopharmaceutical company headquartered in Princeton, New Jersey, specializing in the discovery and development of medicines for serious diseases. The company's portfolio is heavily weighted toward oncology, hematology, and immunology, featuring blockbuster treatments such as Opdivo and Eliquis. Onureg, an oral formulation of azacitidine, is a key component of its hematology franchise, specifically approved for the maintenance treatment of adult patients with acute myeloid leukemia. Following its landmark acquisition of Celgene in 2019, BMS has continued to expand its pipeline through strategic acquisitions in cell therapy, radiopharmaceuticals, and neuroscience. The company operates as a fully integrated pharmaceutical entity with extensive global manufacturing and commercialization capabilities.